Lipum is a clinical-phase biotech company developing first-in-class biologic therapies for chronic inflammatory diseases. Its lead asset, SOL-116, is a humanized antibody targeting the novel BSSL pathway and has completed a Phase 1 trial, supporting further development for rheumatoid arthritis. The company recently completed a merger with Flerie in March 2026, operates with a lean, virtual R&D model utilizing external partners, and has secured significant EU grant funding.
Rheumatoid ArthritisChronic Inflammatory Diseases
Technology Platform
Development of humanized monoclonal antibodies targeting the Bile Salt-Stimulated Lipase (BSSL), a novel pro-inflammatory target in the immune system.
Funding History
2
Total raised:$12.5M
Series A$10MIndustrifonden
Seed$2.5MUmeå Biotech Incubator
Opportunities
The primary opportunity is addressing the large, underserved rheumatoid arthritis market with a first-in-class therapy offering a novel mechanism of action.
Success in RA would validate the BSSL platform and create significant opportunities to expand into other chronic inflammatory diseases with high unmet need, such as psoriasis or inflammatory bowel disease.
Risk Factors
The key risk is clinical failure of the novel BSSL target in upcoming Phase 2 trials.
Additional risks include reliance on third-party contractors (CROs/CDMOs), intense competition in the immunology space, and execution risks associated with the recent merger and integration with Flerie.
Competitive Landscape
Lipum operates in the highly competitive rheumatoid arthritis market, dominated by blockbuster TNF inhibitors and newer JAK inhibitors and IL-6 blockers. Its primary competitive edge is its novel, first-in-class BSSL target, which could offer a differentiated efficacy/safety profile. It will compete against other late-stage novel mechanisms from both large pharma and biotech.
